Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KMDA | 6-K | neutral | 2/10 | Kamada Ltd. filed a 6-K responding to an SEC comment letter regarding its 2025 Form 20-F. The company clarified it did n | Oct 5, 2026 |
| GMAB | 6-K | bullish | 7/10 | Genmab and AbbVie announced positive topline Phase 3 results for epcoritamab + R-CHOP in newly diagnosed DLBCL, showing | Oct 5, 2026 |
| ARQT | SC 13G/A | neutral | 3/10 | BlackRock filed an amended Schedule 13G disclosing a 14.1% passive stake in Arcutis Biotherapeutics as of September 30, | Oct 5, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma Inc. filed a Form 6-K with Exhibit 99.1, which is a Certificate and Articles of Amendment. The filing is a | Oct 5, 2026 |
| NEUP | SC 13G | neutral | 3/10 | AdvisorShares Trust disclosed a passive 5.78% stake in Neuphoria Therapeutics Inc. via Schedule 13G, holding 312,895 com | Oct 5, 2026 |
| PBM | SC 13G | neutral | 3/10 | AdvisorShares Trust disclosed a 6.78% passive stake in Psyence Biomedical Ltd. via a new Schedule 13G filing, holding 25 | Oct 5, 2026 |
| QNTM | SC 13G/A | neutral | 3/10 | AdvisorShares Trust filed an amended Schedule 13G disclosing a 4.95% passive stake in Quantum Biopharma Ltd. as of Septe | Oct 5, 2026 |
| BMY | ANALYST-DOWNGRADE | bearish | 4/10 | Leerink Partners double-downgraded BMY from Outperform to Market Perform on October 5, 2026, slashing the price target f | Oct 5, 2026 |
| PMVP | 8-K | bullish | 6/10 | PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, with the press release also announcing the c | Oct 5, 2026 |
| HYPD | SC 13G/A | neutral | 2/10 | Forsakringsaktiebolaget Avanza Pension filed an amended Schedule 13G/A reporting a passive stake of 14,871 shares (0.10% | Oct 5, 2026 |
| JAGX | 8-K | bearish | 7/10 | Jaguar Health declared a special one-time dividend of Series R Convertible Preferred Stock, with each share converting i | Oct 5, 2026 |
| GRML | PRESS-RELEASE | neutral | 4/10 | Greenland Mines exercised its option to acquire an additional 9.9% of AnorTech for ~US$5.3M (C$7.55M), paid in Greenland | Oct 5, 2026 |
| MBRX | 8-K | neutral | 2/10 | Moleculin Biotech filed an 8-K on October 5, 2026, to furnish an investor presentation (Exhibit 99.1) posted on its webs | Oct 5, 2026 |
| COYA | 8-K | neutral | 4/10 | Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALSTARS trial (NCT07161999) evaluating COYA | Oct 5, 2026 |
| IMNM | 8-K | bullish | 6/10 | Immunome entered into Amendment No. 4 to its License Agreement with Bristol-Myers Squibb, paying $20M in cash and issuin | Oct 5, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics granted inducement stock options for 207,150 shares to two new employees under its 2026 Inducement P | Oct 5, 2026 |
| BNTC | 8-K | neutral | 4/10 | Benitec announced receipt of formal FDA feedback from a Type C meeting regarding the BB-301 pivotal study design. The FD | Oct 5, 2026 |
| PCVX | 8-K | bullish | 7/10 | Vaxcyte reported positive topline Phase 3 data from the OPUS-1 pivotal trial of VAX-31, its 31-valent pneumococcal conju | Oct 5, 2026 |
| ARDX | PRESS-RELEASE | neutral | 2/10 | Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, highlighting real-world evidence for tenapa | Oct 5, 2026 |
| RADX | 6-K | bullish | 6/10 | Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, its invest | Oct 5, 2026 |
| RZLT | 8-K | mixed | 6/10 | Rezolute announced that the FDA recommended a pre-BLA meeting as a precursor to submitting a Biologics License Applicati | Oct 5, 2026 |
| ALVO | 6-K | bullish | 6/10 | Alvotech announced FDA approval of a second drug substance manufacturing suite (DSM2) at its Reykjavik facility for SIML | Oct 5, 2026 |
| AZN | 6-K | neutral | 4/10 | AstraZeneca completed its previously announced $2 billion equity investment in Summit Therapeutics, acquiring a strategi | Oct 5, 2026 |
| HROW | 8-K | bullish | 7/10 | Harrow closed its acquisition of worldwide rights to TYRVAYA (varenicline solution) nasal spray from Viatris, excluding | Oct 5, 2026 |
| CBIO | PRESS-RELEASE | neutral | 4/10 | Crescent Biopharma announced FDA clearance of its IND application for CR-002, a topoisomerase inhibitor ADC targeting PD | Oct 5, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio presented new exploratory cardiac data from the Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9 at the World Mus | Oct 5, 2026 |
| TRIB | 6-K | neutral | 2/10 | Trinity Biotech filed a 6-K reporting the results of its annual general meeting held on September 30, 2026. Shareholders | Oct 5, 2026 |
| ATHE | PRESS-RELEASE | bullish | 8/10 | Alterity Therapeutics announced that its Phase 2 trial of ATH434 50 mg in Multiple System Atrophy (MSA) met its primary | Oct 5, 2026 |
| INSM | 8-K | neutral | 4/10 | Insmed announced CFO Sara Bonstein will step down on October 30, 2026, with a search underway for a successor. The compa | Oct 5, 2026 |
| ALEC | 8-K | bullish | 7/10 | Alector entered an exclusive global license agreement with Genentech for its AL050 GCase enzyme replacement therapy prog | Oct 5, 2026 |